Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Oliver Politz

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
The Biochemical Journal|February 7, 2002
Stabilin-1 and -2 constitute a novel family of fasciclin-like hyaluronan receptor homologuesOliver Politz, Alexei Gratchev, Peter A G McCourt, et al.
International Journal of Cancer|February 27, 2019
Rogaratinib: A potent and selective pan-FGFR inhibitor with broad antitumor activity in FGFR-overexpressing preclinical cancer modelsSylvia Grünewald, Oliver Politz, Sebastian Bender, et al.
International Journal of Cancer|October 5, 2016
BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse modelsOliver Politz, Franziska Siegel, Lars Bärfacker, et al.
Molecular Cancer Therapeutics|June 26, 2023
A Targeted Thorium-227 Conjugate Demonstrates Efficacy in Preclinical Models of Acquired Drug Resistance and Combination Potential with Chemotherapeutics and Antiangiogenic TherapiesSabine Zitzmann-Kolbe, Alexander Kristian, Dieter Zopf, et al.
British Journal of Haematology|November 27, 2023
The ATR inhibitor elimusertib exhibits anti-lymphoma activity and synergizes with the PI3K inhibitor copanlisibGiulio Sartori, Chiara Tarantelli, Filippo Spriano, et al.
Blood Advances|March 4, 2020
Copanlisib synergizes with conventional and targeted agents including venetoclax in B- and T-cell lymphoma modelsChiara Tarantelli, Martin Lange, Eugenio Gaudio, et al.
Molecular Oncology|January 15, 2024
Dual targeting of the androgen receptor and PI3K/AKT/mTOR pathways in prostate cancer models improves antitumor efficacy and promotes cell apoptosisTatsuo Sugawara, Ekaterina Nevedomskaya, Simon Heller, et al.
British Journal of Haematology|February 1, 2020
Evaluation of the PIK3 pathway in peripheral T-cell lymphoma and NK/T-cell lymphomaDachuan Huang, Tammy Linlin Song, Maarja-Liisa Nairismägi, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
The Biochemical Journal|February 7, 2002
Stabilin-1 and -2 constitute a novel family of fasciclin-like hyaluronan receptor homologuesOliver Politz, Alexei Gratchev, Peter A G McCourt, et al.
International Journal of Cancer|February 27, 2019
Rogaratinib: A potent and selective pan-FGFR inhibitor with broad antitumor activity in FGFR-overexpressing preclinical cancer modelsSylvia Grünewald, Oliver Politz, Sebastian Bender, et al.
International Journal of Cancer|October 5, 2016
BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse modelsOliver Politz, Franziska Siegel, Lars Bärfacker, et al.
Molecular Cancer Therapeutics|June 26, 2023
A Targeted Thorium-227 Conjugate Demonstrates Efficacy in Preclinical Models of Acquired Drug Resistance and Combination Potential with Chemotherapeutics and Antiangiogenic TherapiesSabine Zitzmann-Kolbe, Alexander Kristian, Dieter Zopf, et al.
British Journal of Haematology|November 27, 2023
The ATR inhibitor elimusertib exhibits anti-lymphoma activity and synergizes with the PI3K inhibitor copanlisibGiulio Sartori, Chiara Tarantelli, Filippo Spriano, et al.
Blood Advances|March 4, 2020
Copanlisib synergizes with conventional and targeted agents including venetoclax in B- and T-cell lymphoma modelsChiara Tarantelli, Martin Lange, Eugenio Gaudio, et al.
Molecular Oncology|January 15, 2024
Dual targeting of the androgen receptor and PI3K/AKT/mTOR pathways in prostate cancer models improves antitumor efficacy and promotes cell apoptosisTatsuo Sugawara, Ekaterina Nevedomskaya, Simon Heller, et al.
British Journal of Haematology|February 1, 2020
Evaluation of the PIK3 pathway in peripheral T-cell lymphoma and NK/T-cell lymphomaDachuan Huang, Tammy Linlin Song, Maarja-Liisa Nairismägi, et al.
Pageof 2